+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biomarkers in Parkinson’s Disease - Overview

  • ID: 3066992
  • Report
  • August 2014
  • Region: Global
  • 81 Pages
  • Insight Pharma Reports
Biomarkers in Parkinson’s Disease is focused on the biomarker identification and development in patients with Parkinson’s Disease. This report focuses on the Parkinson’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the use of biomarkers for Parkinson’s Disease, Biomarkers in Parkinson’s Disease captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Experts interviewed in this report include:

Dr. Andrew West, Associate Professor of Neurology and Neurobiology and Co-Director, Center for Neurodegeneration and Experimental Therapeutics.
Dr. Xuemei Huang, Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology. Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology.
Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers.

Also available in this report is extensive survey data exclusively conducted for this report. Illustrated by 30 figures captured in an in-depth analysis, this section features insight into targets under investigation, challenges, advantages, and desired features of future diagnostic applications.
Note: Product cover images may vary from those shown
Executive Summary

Chapter 1: The Focus Of This Report

Chapter 2: Biomarkers And Their Clinical Utility

What Are Biomarkers?
Advantages Of Biomarkers
Clinical Endpoints Vs. Surrogate Endpoints
Advantages Of Biomarkers As Surrogate Endpoints
Disadvantages To Biomarkers As Surrogate Endpoints
How Are Biomarkers Validated?

Chapter 3: Biomarkers In Neurodegenerative Disorders

Chapter 4: Parkinson’S Disease

What Is Parkinson’S Disease?
Genetic Factors Linked To Parkinson’S Disease
Park2 (Parkin/Ubiquitin E3 Ligase)
Pink1 (Pten-Induced Kinase 1 Protein)
Gba (Glucocerebrosidase)
Promising Biomarkers For Parkinson’S Disease
Snca (A-Synuclein)
Park7 (Dj-1 Protein)
Lrrk2 (Dardarin Protein)
Other Biomarkers
Interview With Dr. Andrew West
Research Background
Lrrk2 Protein Kinase
Advantages
Challenges And Limitations
Parkinson’S Disease Outlook

Chapter 5: Penn State Hershey Medical Center

Research Background
Mri For Parkinson’S Disease Diagnosis
Interview With Dr. Xuemei Huang
Research Background
Non-Invasive Imaging Tool
Advantages
Challenges And Limitations
Parkinson’S Disease Outlook

Atlantic Biomarkers

Research Background
Mass-Spectrometry Assays For Biomarkers
Impact On Healthcare
Interview With Dr. Andreas Jeromin
Company Background
Neurobiomarker Research
Mass Spectrometry-Based Assays

Chapter 6: Survey Results

Chapter 7: Clinical Trials And Pipeline Information In Parkinson’S Disease

References
Note: Product cover images may vary from those shown

Loading
LOADING...

Biomarkers have been a heavily studied topic of interest, and recently on the rise is the interest in neurodegenerative disorders, particularly Parkinson’s Disease. Although there are many techniques used to track Parkinson's Disease progression, this report will primarily focus on blood-based and cerebrospinal fluid-based biomarkers currently under investigation. In addition to covering extensive background information, this report will also highlight market growth and outlook, and feature clinical trial and pipeline information.

After the introduction, Chapters 2 and 3 highlight background information on neurodegenerative disorders and include definitions and elaborate examples of different types of biomarkers used in the clinic. Chapter 2 concludes with market growth, advantages of biomarkers, disadvantages of biomarkers, and validation techniques. Chapters 3 gives a brief overview of neurodegenerative disorders, also speaking to the market growth and rise in interest in biomarkers over the years.

Chapter 4 gives specifics on Parkinson’s Disease, featuring definitions, symptoms, genetic markers, and current research. As the second leading cause of neurodegeneration in the aging population, researchers are scrambling to find biomarkers that will provide enough information for therapeutic action. Featured in this chapter is an interview with Dr. Andrew West, who speaks about his research and successes with the gene LRRK2. This chapter also provides an extensive amount of detail speaking to genetic targets and their use as biomarkers. Furthermore, Chapter 5 features Dr. Xuemei Huang (Professor and Vice Chair, Department of Neurology; Professor of Neurosurgery, Radiology, Pharmacology, and Kinesiology Director; Hershey Brain Analysis Research Laboratory for Neurodegenerative Disorders, Penn State University-Milton, S. Hershey Medical Center Department of Neurology) and Dr. Andreas Jeromin, CSO and President of Atlantic Biomarkers. These chapters provide insight to utilizing biomarkers as a diagnostic for Parkinson’s Disease.

Chapter 6 includes an elaborate survey analysis exclusively done for this report. Qualifying participants worked with neurobiomarkers, neurodiagnostics, or both. With over 30 survey figures depicting the general R&D group working in this space, this section provides information including: research demographics, targets under investigation, challenges, advantages, and desired features of future diagnostic applications.
Note: Product cover images may vary from those shown
Adroll
adroll